Pre-release: this release has not been published. Identifiers are permanent; descriptions may still change.
21 U.S.C. 356 Expedited approval of drugs for serious or life-threatening diseases or conditions
21 U.S.C. 356 Expedited approval of drugs for serious or life-threatening diseases or conditions, “Expedited approval of drugs for serious or life-threatening diseases or conditions”, is a U.S. Code section of Part A—Drugs and Devices; in force.
https://ontology.bommaritollc.com/id/01a0f06c-cce5-749b-bd0a-9561cfcbbfe8
Elsewhere
Facts
| adms:identifier | |
| eli:cites | |
| prov:wasDerivedFrom | |
| schema:isPartOf | |
| schema:legislationIdentifier | 21 U.S.C. 356 |
| schema:legislationJurisdiction | |
| schema:legislationLegalForce | |
| schema:legislationType | |
| schema:name | Expedited approval of drugs for serious or life-threatening diseases or conditionsen |
| schema:url | |
| skos:prefLabel | 21 U.S.C. 356 Expedited approval of drugs for serious or life-threatening diseases or conditionsen |
Related
Cited by (12)eli:cites
- 21 U.S.C. 331 Prohibited acts
- 21 U.S.C. 355 New drugs
- 21 U.S.C. 356-1 Accelerated approval of priority countermeasures
- 21 U.S.C. 356-2 Accelerated approval Council
- 21 U.S.C. 356b Reports of postmarketing studies
- 21 U.S.C. 356g Standards for regenerative medicine and regenerative advanced therapies
- 21 U.S.C. 357 Qualification of drug development tools
- 21 U.S.C. 360bbb-0 Expanded access policy required for investigational drugs
- 21 U.S.C. 360bbb-3c Expedited development and review of medical products for emergency uses
- 21 U.S.C. 360ff Priority review to encourage treatments for rare pediatric diseases
- 21 U.S.C. 387r Drug products used to treat tobacco dependence
- 42 U.S.C. 247d-5 Combating antimicrobial resistance
Amended by (3)eli:amends
Rules made under it (3)eli:based_on
- 21 CFR Part 208—Medication Guides for prescription drug products
- 21 CFR Part 230—Certification and postmarketing reporting for designated medical gases (Eff. 12-18-25)
- 21 CFR Part 314—Applications for FDA approval to market a new drug